Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
360 participants
INTERVENTIONAL
2023-05-16
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori
NCT04879992
Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
NCT05726734
High Dose of Dual Therapy Plus Metronidazole for Helicobacter Pylori RescueTreatment
NCT04024527
Tailored Therapy for Helicobacter Pylori Rescue Treatment
NCT03413020
The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection
NCT05620589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tetracycline Bismuth Quadruple Therapy
Vonoprazan 20mg bid, Bismuth Potassium Citrate 110mg qid, Tetracycline 500mg qid, Metronidazole 400mg qid
Vonoprazan
Proton pump inhibitor
Bismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Tetracycline
Antibiotics for H. pylori eradication
Metronidazole
Antibiotics for H. pylori eradication
Rifabutin Triple Therapy
Vonoprazan 20mg bid, amoxicillin 1000mg tid, rifabutin 150mg bid
Vonoprazan
Proton pump inhibitor
Amoxicillin
Antibiotics for H. pylori eradication
Rifabutin
Antibiotics for H. pylori eradication
Dual Therapy
Vonoprazan 20mg bid, amoxicillin 1000mg tid
Vonoprazan
Proton pump inhibitor
Amoxicillin
Antibiotics for H. pylori eradication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vonoprazan
Proton pump inhibitor
Bismuth Potassium Citrate
Gastric mucosal protective drug with anti-H. pylori effect
Tetracycline
Antibiotics for H. pylori eradication
Metronidazole
Antibiotics for H. pylori eradication
Amoxicillin
Antibiotics for H. pylori eradication
Rifabutin
Antibiotics for H. pylori eradication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed H. pylori infection and with previous treatment experience
Exclusion Criteria
* under 18 or over 80 years old
* history of gastrectomy
* pregnant or lactating women
* Previous history of tuberculosis
* Allergy to any of the study drugs
* severe systemic diseases or malignancy
* administration of antibiotics, bismuth, antisecretory drugs, or Chinese herb medicine in the preceding 8 weeks
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Lu, MD
Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Shanghai Songjiang District Central Hospital
Shanghai, Shanghai Municipality, China
The Second Affiliated Hospital of Zhejiang University school of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rjhy20230001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.